Sandoz has filed a petition for inter partes review of AbbVie’s U.S. Patent No. 8,802,100 (IPR2017-01823), which claims stable formulations of an anti-TNFα antibody identified in the petition as Humira® (adalimumab). Sandoz also filed a petition for inter partes review of AbbVie’s U.S. Patent No. 9,512,216 (IPR2017-01824), which claims a dosing regimen of an antibody identified in the petition as Humira® to treat chronic plaque psoriasis.
These petitions and other selected PTAB filings concerning biologics are posted on our IPR Tracker Page.
